EUVIMEDEUVIMED entdecken
Open Access

Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19

Melisa M Shah iD, Brendan Joyce, Ian D Plumb, Sam Sahakian, Leora R Feldstein, Eric Barkley, Mason Paccione, Joseph Deckert, Danessa Sandmann, Melissa Briggs Hagen, Jacqueline L Gerhart

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciae105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Melisa M Shah und 10 weiteren Autor:innen. Beteiligte Einrichtung: Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preven…. Hauptthemen laut MEDLINE: Ritonavir, Hospitalization, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, Epic Research, CDC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19–.24). Eligible adults, including those previously vaccinated, should be considered for COVID-19 antiviral treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirHospitalizationCOVID-19SARS-CoV-2Antiviral AgentsCOVID-19 VaccinesHumansMaleMiddle AgedFemaleAdultAgedVaccinationLeucineCOVID-19 Drug TreatmentLactamsNitrilesProline

Stichwörter der Autor:innen

COVID-19SARS-CoV-2nirmatrelvir-ritonavirvaccination

Substanzen

RitonavirAntiviral AgentsCOVID-19 VaccinesnirmatrelvirLeucineLactamsNitrilesProline

Autor:innen und Institutionen

  • Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Epic Research, Epic Systems Corporation, Verona, Wisconsin, USA.

ORCID-Profile: Melisa M Shah

Förderung

  • Intramural CDC HHS
  • Epic Research
  • CDC
  • Epic Systems Corporation

Zitieren

APA

Shah, M. M., Joyce, B., Plumb, I. D., Sahakian, S., Feldstein, L. R., Barkley, E., Paccione, M., Deckert, J., Sandmann, D., Hagen, M. B., & Gerhart, J. L. (2024). Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae105

Vancouver

Shah MM, Joyce B, Plumb ID, Sahakian S, Feldstein LR, Barkley E, et al. Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae105

BibTeX
@article{Shah2024,
  author = {Shah, Melisa M and Joyce, Brendan and Plumb, Ian D and Sahakian, Sam and Feldstein, Leora R and Barkley, Eric and Paccione, Mason and Deckert, Joseph and Sandmann, Danessa and Hagen, Melissa Briggs and Gerhart, Jacqueline L},
  title = {Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciae105}
}
Kostenlos starten →